Inventaire - your friends and communities are your best library

Brentuximab vedotin

author

Niels W C J van de Donk

published in: Monoclonal Antibodies

date of publication: 2012-07-01

Cites articles 51

Date

Title

Authors

2012-05-21

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

Barbara Pro, Tim M. Illidge, Joseph M Connors, Michelle A Fanale, Ranjana H. Advani, Nancy L Bartlett
2012-03-26

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Joseph M Connors, Nancy L Bartlett, Bruce D. Cheson
2011-12-06

Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009.

Cat Halthur, Paul W Dickman, Ola Landgren
2011-11-01

OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function
2011-09-21

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Todd A Fehniger, David D. Hurd, Nancy L Bartlett, Kristie A Blum, Amanda Cashen, Kathryn M. Trinkaus, Marilyn J Siegel
2011-08-12

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Emilio Berti, José A. Sanches, Emmilia Hodak, Werner Kempf
2011-07-25

Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice

David R Withers, Vasileios Bekiaris, Lucy Walker, Graham Anderson
2011-06-28

Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools

Olaf Merkel, Lukas Kenner, Frank Hamacher, Eveline Sifft
2011-04-11

Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).

British Committee for Standards in Haematology, Claire E. Dearden
2011-02-25

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Steven Allen, Elaine Jaffe, Susan E Bates, Tito Fojo, William Douglas Figg, Sr., Seth M Steinberg, Richard L Piekarz
2011-11-23

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Andrew M Evens, Leo Gordon, Reem Karmali, Benjamin Parsons, Sonali M Smith, Chadi Nabhan, Irene B Helenowski, Erika Ramsdale, Britt Hanson, June M McKoy
2011-11-11

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

Nancy L Bartlett, Michelle A Fanale, Ranjana H. Advani
2011-10-10

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

Nancy L Bartlett, Amanda Cashen
2010-01-01

Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma

Kristie A Blum
2010-11-01

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

Nancy L Bartlett
2010-09-29

The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
2010-04-27

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

Cancer and Leukemia Group B, Nancy L Bartlett, Kristie A Blum, Bruce D. Cheson
2010-05-01

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
2010-01-19

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate
2010-07-14

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

John Radford, Mats Jerkeman, Hans Hagberg
2009-08-03

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

Debra M Sarasohn, Paul Hamlin, Andrew D Zelenetz, Owen A O'Connor, Steven M Horwitz
2009-09-29

A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.
2009-05-19

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Nancy L Bartlett, Ajay K Gopal
2009-04-28

In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma
2008-05-08

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

Iqbal S Grewal
2008-04-02

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

Fred A. Ullrich, Julie M Vose, Randy D Gascoyne, James O Armitage, Dennis D Weisenburger, Joseph M Connors, Elaine Jaffe, Stefano A Pileri, Lisa M Rimsza, Kerry J Savage, Nancy Lee Harris, Mukesh Chhanabhai, International Peripheral T-Cell Lymphoma Project
2008-11-01

A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection

Worawidh Wajjwalku
2007-12-13

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Nancy L Bartlett
2007-12-20

Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients

Hermann Brenner
2007-05-21

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
2006-06-01

Deciphering CD30 ligand biology and its role in humoral immunity
2006-10-01

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

Jeffrey S. Miller, Margaret L MacMillan

Article - wd:Q38017578

Welcome to Inventaire

the library of your friends and communities

learn more